Drug Profile
Pegylated integrated interferon mutant - Beijing Tri-Prime Genetic Engineering
Alternative Names: PEG-IIFNmLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Beijing Tri-Prime Genetic Engineering
- Class Antivirals; Interferons
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis C
Most Recent Events
- 29 Aug 2019 Discontinued - Phase-II for Hepatitis B in China (Parenteral)
- 29 Aug 2019 Discontinued - Phase-II for Hepatitis C in China (Parenteral)